AK129 + oxaliplatin + capecitabine

AK129 + oxaliplatin + capecitabine is a combination regimen under investigation for the first-line treatment of unresectable, locally advanced, or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma in patients who are HER2-negative. - **AK129** is a bispecific monoclonal antibody targeting both PD-1 and LAG-3, checkpoint molecules involved in tumor immune evasion. - **Oxaliplatin** is a platinum-based chemotherapy that induces DNA cross-linking and inhibits DNA synthesis, thus promoting cancer cell death. - **Capecitabine** is an orally administered prodrug converted to 5-fluorouracil (5-FU) in tumor tissues, inhibiting DNA synthesis and cell division. This combination leverages immunotherapy (AK129) with cytotoxic chemotherapy (oxaliplatin + capecitabine, also known as XELOX or CAPOX) to enhance anti-tumor efficacy[1][3][5][6]. The combination is currently being evaluated in Phase 1/2 trials for advanced HER2-negative gastric and GEJ adenocarcinoma[1].

Brand names

XELOXCAPOX

Other names

oxaliplatin + capecitabinecapecitabine + oxaliplatinAK129 + XELOXAK129 + CAPOX